A phase II evaluation of Bexarotene (Targretin®) capsules in patients with metastatic melanoma

Agop Y. Bedikian; Carl Plager; Nicholas Papadopoulos; Julie Ellerhorst; Teri Smith; Robert S. Benjamin

doi:10.3892/or.7.4.883

A phase II evaluation of Bexarotene (Targretin®) capsules in patients with metastatic melanoma

Agop Y. Bedikian, Carl Plager, Nicholas Papadopoulos, Julie Ellerhorst, Teri Smith, Robert S. Benjamin

Sarcoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

A phase II study was undertaken to determine the efficacy of Bexarotene in melanoma. Between November 1997 and April 1998, 19 patients were given Bexarotene in single daily oral doses of 450 mg/m² in capsule form continuously. Nineteen patients, four with choroidal metastatic melanoma, were treated. No responses were seen. Five patients had stable disease, two of the four with choroidal melanoma, had tumor progression. Myelosuppression was mild. Grade 3 myalgia, asthenia, diarrhea, cold hands/feet, and mood changes were seen in one patient each. Changes in serum triglyceride and thyroxine levels were common. Bexarotene, as used in this study, is not effective against melanoma.

Original language	English (US)
Pages (from-to)	883-886
Number of pages	4
Journal	Oncology reports
Volume	7
Issue number	4
DOIs	https://doi.org/10.3892/or.7.4.883
State	Published - 2000

Keywords

Bexarotene
Chemotherapy
Melanoma

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3892/or.7.4.883

Cite this

@article{3cfe0b6c5ad74d14bbbf8592eeb4863c,

title = "A phase II evaluation of Bexarotene (Targretin{\textregistered}) capsules in patients with metastatic melanoma",

abstract = "A phase II study was undertaken to determine the efficacy of Bexarotene in melanoma. Between November 1997 and April 1998, 19 patients were given Bexarotene in single daily oral doses of 450 mg/m2 in capsule form continuously. Nineteen patients, four with choroidal metastatic melanoma, were treated. No responses were seen. Five patients had stable disease, two of the four with choroidal melanoma, had tumor progression. Myelosuppression was mild. Grade 3 myalgia, asthenia, diarrhea, cold hands/feet, and mood changes were seen in one patient each. Changes in serum triglyceride and thyroxine levels were common. Bexarotene, as used in this study, is not effective against melanoma.",

keywords = "Bexarotene, Chemotherapy, Melanoma",

author = "Bedikian, {Agop Y.} and Carl Plager and Nicholas Papadopoulos and Julie Ellerhorst and Teri Smith and Benjamin, {Robert S.}",

year = "2000",

doi = "10.3892/or.7.4.883",

language = "English (US)",

volume = "7",

pages = "883--886",

journal = "Oncology reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "4",

}

TY - JOUR

T1 - A phase II evaluation of Bexarotene (Targretin®) capsules in patients with metastatic melanoma

AU - Bedikian, Agop Y.

AU - Plager, Carl

AU - Papadopoulos, Nicholas

AU - Ellerhorst, Julie

AU - Smith, Teri

AU - Benjamin, Robert S.

PY - 2000

Y1 - 2000

N2 - A phase II study was undertaken to determine the efficacy of Bexarotene in melanoma. Between November 1997 and April 1998, 19 patients were given Bexarotene in single daily oral doses of 450 mg/m2 in capsule form continuously. Nineteen patients, four with choroidal metastatic melanoma, were treated. No responses were seen. Five patients had stable disease, two of the four with choroidal melanoma, had tumor progression. Myelosuppression was mild. Grade 3 myalgia, asthenia, diarrhea, cold hands/feet, and mood changes were seen in one patient each. Changes in serum triglyceride and thyroxine levels were common. Bexarotene, as used in this study, is not effective against melanoma.

AB - A phase II study was undertaken to determine the efficacy of Bexarotene in melanoma. Between November 1997 and April 1998, 19 patients were given Bexarotene in single daily oral doses of 450 mg/m2 in capsule form continuously. Nineteen patients, four with choroidal metastatic melanoma, were treated. No responses were seen. Five patients had stable disease, two of the four with choroidal melanoma, had tumor progression. Myelosuppression was mild. Grade 3 myalgia, asthenia, diarrhea, cold hands/feet, and mood changes were seen in one patient each. Changes in serum triglyceride and thyroxine levels were common. Bexarotene, as used in this study, is not effective against melanoma.

KW - Bexarotene

KW - Chemotherapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=0034219447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034219447&partnerID=8YFLogxK

U2 - 10.3892/or.7.4.883

DO - 10.3892/or.7.4.883

M3 - Review article

C2 - 10854563

AN - SCOPUS:0034219447

SN - 1021-335X

VL - 7

SP - 883

EP - 886

JO - Oncology reports

JF - Oncology reports

IS - 4

ER -

A phase II evaluation of Bexarotene (Targretin®) capsules in patients with metastatic melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this